Clinical Trials Directory

Trials / Completed

CompletedNCT04259892

Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.

Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection

Status
Completed
Phase
Study type
Observational
Enrollment
324 (actual)
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France · Other Government
Sex
All
Age
Healthy volunteers
Not accepted

Summary

In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on March, 16th 2020. Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2 in the community and within the hospital. Depending on the country, contact subjects considered to be at high or moderate risk of SARS-CoV-2 are, either isolated at home for a period of time defined by the health authorities or, on the contrary, continue their professional activity on the condition that they adopt measures to prevent transmission to those around them. In most European countries, healthcare workers adopt this second option. In all cases, it is most often recommended that contact persons monitor their state of health and communicate it to the persons dedicated to this action. Whether such subjects become spreaders of the virus is not known, nor is the proportion of viral spreader who will develop a symptomatic infection.

Detailed description

Procedures added by the research: Phone calls for collection of reported symptoms. Nasopharyngeal swabs for determination of the presence of SARS-CoV-2 detected by PCR. Blood sampling for determination of the presence of SARS-CoV-2 IgM or IgG. Saliva or blood sampling for whole exome sequencing of the subject.

Conditions

Interventions

TypeNameDescription
BIOLOGICAL2019-nCoV PCRNasopharyngeal swabs

Timeline

Start date
2020-02-04
Primary completion
2021-08-02
Completion
2021-08-02
First posted
2020-02-07
Last updated
2024-07-30

Locations

16 sites across 2 countries: France, French Guiana

Source: ClinicalTrials.gov record NCT04259892. Inclusion in this directory is not an endorsement.